Supplementary Table 1. Uni- and multivariate analysis of progression-free survival in patients with HCC treated with nivolumab.

Variable	Univariable HR (95% CI)	p value	Multivariable HR (95% CI)	p value
Baseline AFP, >400/<400 IU/mL	1.30 (0.85-1.99)	0.22		
BCLC Stage, C+D/A+B	2.82 (1.46-5.44)	**0.002***	2.58 (1.33-5.01)	**0.005***
Child-Pugh, B/A	1.04 (0.66-1.62)	0.86		
Cirrhosis, present/absent	1.01 (0.66-1.54)	0.97		
Concomitant steroid use, present/absent	0.95 (0.65-1.39)	0.95		
Objective response CR+PR/SD+PD	0.26 (0.18-0.39)	**<0.001***	0.20 (0.11-0.37)	**<0.001***
ECOG-PS, 0/1-3	0.60 (0.25-1.44)	0.25		
Extrahepatic spread, present/absent	1.04 (0.56-1.93)	0.89		
Immunotherapy line, 1st/2nd-4th	0.60 (0.39-0.93)	**0.02***	0.60 (0.38-0.93)	**0.023**
PVT, present/absent	1.09 (0.58-2.03)	0.80		

Supplementary Table 2. Baseline patient characteristics stratified according to line of therapy.

		1L (%)	>1L (%)	χ^2 test p value
AFP >400 iU/mL (n=225)		36/84 (42.9)	57/141 (40.4)	0.72
BCLC stage (n=233)	A-B	23/85 (27.1)	31/148 (20.9)	0.29
	C-D	62/85 (72.9)	117/148 (79.1)	
Cirrhosis (n-233)		65/85 (76.5)	111/148 (75.0)	0.80
Concomitant steroid use (n=233)		30/85 (35.3)	38/148 (25.7)	0.12
CP class (n=233)	A	54/85 (63.5)	104/148 (70.3)	0.29
	B	31/85 (36.5)	44/148 (29.7)	
ECOG PS (n=157)	0	4/27 (14.8)	23/112 (20.5)	0.29
	1-3	23/27 (85.2)	89/112 (79.5)	
Extrahepatic spread (n=157)		10/27 (37.0)	56/113 (49.6)	0.24
Objective response (n=233)		21/85 (24.7)	28/148 (18.9)	0.30
Portal vein thrombosis (n=157)		8/27 (29.6)	51/113 (34.5)	0.14
Post-ICI active anti-cancer therapy (n=140)		9/27 (33.3)	33/113 (29.2)	0.67